260 related articles for article (PubMed ID: 34533562)
21. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma.
Baqai U; Kurimchak AM; Trachtenberg IV; Purwin TJ; Haj JI; Han A; Luo K; Pachon NF; Jeon A; Chua V; Davies MA; Gutkind JS; Benovic JL; Duncan JS; Aplin AE
J Biol Chem; 2023 Dec; 299(12):105418. PubMed ID: 37923138
[TBL] [Abstract][Full Text] [Related]
22. Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation.
Cerne JZ; Hartig SM; Hamilton MP; Chew SA; Mitsiades N; Poulaki V; McGuire SE
Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2130-9. PubMed ID: 24595385
[TBL] [Abstract][Full Text] [Related]
23. Targeting GNAQ/11 through PKC inhibition in uveal melanoma.
Lietman CD; McKean M
Cancer Gene Ther; 2022 Dec; 29(12):1809-1813. PubMed ID: 35181742
[TBL] [Abstract][Full Text] [Related]
24. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
[TBL] [Abstract][Full Text] [Related]
25. Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.
Bahr JC; Robey RW; Luchenko V; Basseville A; Chakraborty AR; Kozlowski H; Pauly GT; Patel P; Schneider JP; Gottesman MM; Bates SE
Oncotarget; 2016 Oct; 7(43):69804-69815. PubMed ID: 27634878
[TBL] [Abstract][Full Text] [Related]
26. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
Wang Y; Liu M; Jin Y; Jiang S; Pan J
Cancer Lett; 2017 Aug; 400():47-60. PubMed ID: 28455241
[TBL] [Abstract][Full Text] [Related]
28. Combined Inhibition of Gα
Hitchman TD; Bayshtok G; Ceraudo E; Moore AR; Lee C; Jia R; Wang N; Pachai MR; Shoushtari AN; Francis JH; Guan Y; Chen J; Chang MT; Taylor BS; Sakmar TP; Huber T; Chi P; Chen Y
Clin Cancer Res; 2021 Mar; 27(5):1476-1490. PubMed ID: 33229459
[TBL] [Abstract][Full Text] [Related]
29. Artemisinin Inhibits the Migration and Invasion in Uveal Melanoma via Inhibition of the PI3K/AKT/mTOR Signaling Pathway.
Farhan M; Silva M; Xingan X; Zhou Z; Zheng W
Oxid Med Cell Longev; 2021; 2021():9911537. PubMed ID: 34931134
[TBL] [Abstract][Full Text] [Related]
30. Mutations in GNA11 in uveal melanoma.
Van Raamsdonk CD; Griewank KG; Crosby MB; Garrido MC; Vemula S; Wiesner T; Obenauf AC; Wackernagel W; Green G; Bouvier N; Sozen MM; Baimukanova G; Roy R; Heguy A; Dolgalev I; Khanin R; Busam K; Speicher MR; O'Brien J; Bastian BC
N Engl J Med; 2010 Dec; 363(23):2191-9. PubMed ID: 21083380
[TBL] [Abstract][Full Text] [Related]
31. The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence.
Moschos MM; Dettoraki M; Androudi S; Kalogeropoulos D; Lavaris A; Garmpis N; Damaskos C; Garmpi A; Tsatsos M
Anticancer Res; 2018 Jul; 38(7):3817-3824. PubMed ID: 29970501
[TBL] [Abstract][Full Text] [Related]
32. Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma.
Glinkina KA; Teunisse AFAS; Gelmi MC; de Vries J; Jager MJ; Jochemsen AG
Melanoma Res; 2023 Oct; 33(5):345-356. PubMed ID: 37467061
[TBL] [Abstract][Full Text] [Related]
33. HDAC Inhibition Enhances the
Faião-Flores F; Emmons MF; Durante MA; Kinose F; Saha B; Fang B; Koomen JM; Chellappan SP; Maria-Engler SS; Rix U; Licht JD; Harbour JW; Smalley KSM
Clin Cancer Res; 2019 Sep; 25(18):5686-5701. PubMed ID: 31227503
[TBL] [Abstract][Full Text] [Related]
34. mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.
Beagle BR; Nguyen DM; Mallya S; Tang SS; Lu M; Zeng Z; Konopleva M; Vo TT; Fruman DA
Oncotarget; 2015 Feb; 6(4):2088-100. PubMed ID: 25576920
[TBL] [Abstract][Full Text] [Related]
35. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.
Park JJ; Stewart A; Irvine M; Pedersen B; Ming Z; Carlino MS; Diefenbach RJ; Rizos H
Cancer Gene Ther; 2022 Oct; 29(10):1384-1393. PubMed ID: 35352024
[TBL] [Abstract][Full Text] [Related]
36. Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.
Chua V; Lapadula D; Randolph C; Benovic JL; Wedegaertner PB; Aplin AE
Mol Cancer Res; 2017 May; 15(5):501-506. PubMed ID: 28223438
[TBL] [Abstract][Full Text] [Related]
37. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ
Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470
[TBL] [Abstract][Full Text] [Related]
38. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical and molecular pathology of ocular uveal melanocytoma: evidence for somatic GNAQ mutations.
Mudhar HS; Doherty R; Salawu A; Sisley K; Rennie IG
Br J Ophthalmol; 2013 Jul; 97(7):924-8. PubMed ID: 23685997
[TBL] [Abstract][Full Text] [Related]
40. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.
Feng X; Degese MS; Iglesias-Bartolome R; Vaque JP; Molinolo AA; Rodrigues M; Zaidi MR; Ksander BR; Merlino G; Sodhi A; Chen Q; Gutkind JS
Cancer Cell; 2014 Jun; 25(6):831-45. PubMed ID: 24882515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]